Palatin Technologies (PTN)
(Real Time Quote from BATS)
$1.79 USD
-0.03 (-1.65%)
Updated Apr 29, 2024 03:56 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
PTN 1.79 -0.03(-1.65%)
Will PTN be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for PTN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PTN
Palatin (PTN) Up 15% on Results From Dry Eye Disease Study
Strength Seen in Repligen (RGEN): Can Its 4.3% Jump Turn into More Strength?
PTN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Kronos Bio, Inc. (KRON) Reports Q3 Loss, Lags Revenue Estimates
Palatin Technologies, Inc. (PTN) Reports Q3 Loss, Tops Revenue Estimates
Alimera Sciences (ALIM) Reports Q1 Loss, Tops Revenue Estimates
Other News for PTN
Palatin Technologies And 2 Other Stocks Under $3 Insiders Are Buying
Biotech Alert: Searches spiking for these stocks today
Biotech Alert: Searches spiking for these stocks today
Buy Rating Affirmed for Palatin Technologies Following Successful Phase 3 Trial of PL9643 for Dry Eye Disease
Biggest stock movers today: Crypto stocks, DCO, PERI, FSLY, and more